These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29141848)

  • 1. MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer.
    Pettersson A; Gerke T; Penney KL; Lis RT; Stack EC; Pértega-Gomes N; Zadra G; Tyekucheva S; Giovannucci EL; Mucci LA; Loda M
    Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):201-207. PubMed ID: 29141848
    [No Abstract]   [Full Text] [Related]  

  • 2. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.
    Antonarakis ES; Keizman D; Zhang Z; Gurel B; Lotan TL; Hicks JL; Fedor HL; Carducci MA; De Marzo AM; Eisenberger MA
    Cancer; 2012 Dec; 118(24):6063-71. PubMed ID: 22674438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics.
    Udager AM; DeMarzo AM; Shi Y; Hicks JL; Cao X; Siddiqui J; Jiang H; Chinnaiyan AM; Mehra R
    Prostate; 2016 Jun; 76(9):845-53. PubMed ID: 27159573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence.
    Hawksworth D; Ravindranath L; Chen Y; Furusato B; Sesterhenn IA; McLeod DG; Srivastava S; Petrovics G
    Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):311-5. PubMed ID: 20820186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.
    Pettersson A; Graff RE; Bauer SR; Pitt MJ; Lis RT; Stack EC; Martin NE; Kunz L; Penney KL; Ligon AH; Suppan C; Flavin R; Sesso HD; Rider JR; Sweeney C; Stampfer MJ; Fiorentino M; Kantoff PW; Sanda MG; Giovannucci EL; Ding EL; Loda M; Mucci LA
    Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1497-509. PubMed ID: 22736790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy.
    Fromont G; Godet J; Peyret A; Irani J; Celhay O; Rozet F; Cathelineau X; Cussenot O
    Hum Pathol; 2013 Aug; 44(8):1617-23. PubMed ID: 23574779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG.
    Pettersson A; Lis RT; Meisner A; Flavin R; Stack EC; Fiorentino M; Finn S; Graff RE; Penney KL; Rider JR; Nuttall EJ; Martin NE; Sesso HD; Pollak M; Stampfer MJ; Kantoff PW; Giovannucci EL; Loda M; Mucci LA
    J Natl Cancer Inst; 2013 Dec; 105(24):1881-90. PubMed ID: 24292212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Mel-18 expression in prostate cancer tissues and correlation with clinicopathologic features.
    Wang W; Lin T; Huang J; Hu W; Xu K; Liu J
    Urol Oncol; 2011; 29(3):244-51. PubMed ID: 19395284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.
    Hamid AA; Gray KP; Huang Y; Bowden M; Pomerantz M; Loda M; Sweeney CJ
    Eur Urol Oncol; 2019 Sep; 2(5):475-482. PubMed ID: 31411988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
    Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
    Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of MYC/PTEN Status by Gene-Protein Assay in Grade Group 2 Prostate Biopsies.
    Salles DC; Vidotto T; Faisal FA; Tosoian JJ; Guedes LB; Muranyi A; Bai I; Singh S; Yan D; Shanmugam K; Lotan TL
    J Mol Diagn; 2021 Aug; 23(8):1030-1041. PubMed ID: 34062284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcription factor FoxM1 is the downstream target of c-Myc and contributes to the development of prostate cancer.
    Pan H; Zhu Y; Wei W; Shao S; Rui X
    World J Surg Oncol; 2018 Mar; 16(1):59. PubMed ID: 29554906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis.
    Gurel B; Iwata T; Koh CM; Jenkins RB; Lan F; Van Dang C; Hicks JL; Morgan J; Cornish TC; Sutcliffe S; Isaacs WB; Luo J; De Marzo AM
    Mod Pathol; 2008 Sep; 21(9):1156-67. PubMed ID: 18567993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression.
    Yang G; Timme TL; Frolov A; Wheeler TM; Thompson TC
    Cancer; 2005 Mar; 103(6):1186-94. PubMed ID: 15712208
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Barry KH; Mohanty K; Erickson PA; Wang D; Shi J; Rose G; Cellini A; Clark K; Ambulos N; Yin J; Yan L; Poulin M; Meyer A; Zhang Y; Bentzen SM; Burke A; Hussain A; Berndt SI
    Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33374332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer.
    Gerke T; Beltran H; Wang X; Lee GM; Sboner A; Karnes RJ; Klein EA; Davicioni E; Yousefi K; Ross AE; Börnigen D; Huttenhower C; Mucci LA; Trock BJ; Sweeney CJ
    Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):584-590. PubMed ID: 30420441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.
    Moul JW; Bettencourt MC; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Bauer JJ
    Surgery; 1996 Aug; 120(2):159-66; discussion 166-7. PubMed ID: 8751578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer.
    Kasperzyk JL; Finn SP; Flavin R; Fiorentino M; Lis R; Hendrickson WK; Clinton SK; Sesso HD; Giovannucci EL; Stampfer MJ; Loda M; Mucci LA
    Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2354-63. PubMed ID: 24130224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions of
    Lin HY; Callan CY; Fang Z; Tung HY; Park JY
    Cancer Epidemiol Biomarkers Prev; 2019 Jun; 28(6):1067-1075. PubMed ID: 30914434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.
    Kim J; Roh M; Abdulkadir SA
    BMC Cancer; 2010 Jun; 10():248. PubMed ID: 20515470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.